About the Company
scpharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that, through our proprietary platform, are designed to enable the subcutaneous administration of therapies previously limited to intravenous (iv) delivery—with the goal of transforming infused therapies, advancing patient care, and reducing healthcare costs.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $SCPH News
scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
Generated 4Q 2023 net FUROSCIX® revenue of $6.1 million, at the upper end of the range provided in January and representing ...
scPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2023 Earnings Call Transcript
Q4 2023 Earnings Call March 13, 2024 scPharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.35, expectations ...
Strong Buy Recommendation for scPharmaceuticals on Furoscix’s Successful Launch and Growth Prospects
Begin your TipRanks Premium journey today. scPharmaceuticals (SCPH) Company Description: scPharmaceuticals, Inc.engages in the development of transformative pharmaceutical products for subcutaneous ...
scPharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
scPharmaceuticals to Participate in Two Upcoming Investor Conferences
BURLINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to ...
scPharmaceuticals Inc (SCPH) Reports Q4 and Full-Year 2023 Financials, Focusing on FUROSCIX Growth
Q4 Revenue: scPharmaceuticals Inc ( NASDAQ:SCPH) reported $6.1 million in net FUROSCIX revenue, a 61% increase from the ...
scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
March 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the ...
scPharmaceuticals Inc (SCPH) Q4 2023 Earnings Call Transcript
Greetings, and welcome to scPharmaceuticals Fourth Quarter and Full year 2023 Earnings Conference Call. At this time, all participants are in listen-only mode. [Operator Instructions] As a ...
scPharmaceuticals, Inc.: scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
Generated 4Q 2023 net FUROSCIX® revenue of $6.1 million, at the upper end of the range provided in January and representing sequential growth of 61% from $3.8 million in 3Q 2023 Generated full-year ...
Loading the latest forecasts...